BioSpace News Archive

Tauriga Sciences, Inc. announced that it has amended, in relevant part, the certificate of incorporation of Tauriga Business Development Corp., a wholly owned Delaware incorporated subsidiary of the Company, to change this subsidiary’s name to Tauriga Pharma Corp., verified as complete by the Delaware Secretary of State’s office on January 7, 2020.

MediWound Ltd. (Nasdaq: MDWD), today announced the expansion of its agreement with GENFA MEDICA SA, granting it the exclusive right to market and distribute NexoBrid® in Ukraine, Lithuania, Latvia and Estonia adding to its current rights to distribute NexoBrid in Russia.

Avitide Inc., the industry leader in the discovery and development of custom affinity purification resins, announce a partnership expansion with Allergan.

Blueprint Medicines Corporation announced corporate goals for 2020, which provide a path to achieve the company’s “2020 Blueprint” strategy for launching its global commercial business.

Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced an expanded Genome Assembly offering through its best-in-class genome assembly services, leveraging its Omni-C Technology, which provides unparalleled uniformity per-base genome coverage

Accuray Incorporated (Nasdaq: ARAY) will be discussing its business and revenue growth expectations for the next three fiscal years at the JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 am PACIFIC / 1:00 pm EASTERN.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance.

Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial Officer

Contextual Genomics and Lab Genomics announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.

The Board of Directors of Enzo Biochem, Inc. responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund regarding the Company’s significant accomplishments.